Defining prognostic variables in recurrent endometrioid endometrial cancer: A 15-year single-institution review

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1078-1083

  Esselen, Katharine M ^a   Boruta, David M ^a   Del Carmen, Marcela ^a   Schorge, John O ^a   Goodman, Annekathryn ^a   Growdon, Whitfield B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Endometrioid endometrial cancer; Recurrence; Survival

Indexed keywords

ABDOMINAL CANCER; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PELVIS CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; RETROSPECTIVE STUDY; UTERUS CANCER; VAGINA CANCER;

CARCINOMA, ENDOMETRIOID; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASSACHUSETTS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 80955161652     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821872f4     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225Y249.
2. Keller D, Kempson RL, Levine G, et al. Management of the patient with early endometrial carcinoma. Cancer. 1974;33:1108Y1116.
3. Fleming GF, Fowler JM, Waggoner SE, et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19:1021Y1029. (Pubitemid 32176277)
4. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404Y1411. (Pubitemid 30215963)
5. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201Y209. (Pubitemid 36457866)
6. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744Y751. (Pubitemid 38251372)
7. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19:364Y367. (Pubitemid 32112847)
8. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736Y1744. (Pubitemid 29269242)
9. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520Y529. (Pubitemid 43729963)
10. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463Y469. (Pubitemid 38388137)
11. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2002;9:145Y184.
12. van Wijk FH, van der Burg ME, Burger CW, et al. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer. 2009;19:314Y320.
13. Fujimoto T, Nanjyo H, Fukuda J, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol. 2009;112:342Y347.
14. Mariani A, Webb MJ, Keeney GL, et al. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002;87:274Y280. (Pubitemid 36034647)
15. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55Y65.
16. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003;56:1366Y1372. (Pubitemid 36842889)
17. Gadducci A, Cosio S, Fanucchi A, et al. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res. 2000;20: 1977Y1984. (Pubitemid 30636168)
18. Berchuck A, Anspach C, Evans AC, et al. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol. 1995;59:20Y24.
19. Lin LL, Grigsby PW, Powell MA, et al. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;63:500Y504. (Pubitemid 41317167)
20. Jereczek-Fossa B, Badzio A, Jassem J. Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:405Y413.